• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Philip Morris International Inc

    10/27/25 6:57:10 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    FWP 1 tm2529103d3_fwp.htm FWP

     

    Filed Pursuant to Rule 433

    Registration No. 333-269690

     

    FINAL TERM SHEET

     

    Philip Morris International Inc.

     

    Dated October 27, 2025

     

    Floating Rate Notes due 2028

    3.875% Notes due 2028

    4.000% Notes due 2030

    4.250% Notes due 2032

    4.625% Notes due 2035

     

    Issuer:

    Philip Morris International Inc.

     

    Offering Format:

    SEC Registered

     

    Security:

    Floating Rate Notes due 2028 (the “Floating Rate Notes”)

    3.875% Notes due 2028 (the “2028 Notes”)

    4.000% Notes due 2030 (the “2030 Notes”)

    4.250% Notes due 2032 (the “2032 Notes”)

    4.625% Notes due 2035 (the “2035 Notes”)

     

    Aggregate Principal Amount:

    Floating Rate Notes: $300,000,000

    2028 Notes: $750,000,000

    2030 Notes: $750,000,000

    2032 Notes: $850,000,000

    2035 Notes: $850,000,000

     

    Maturity Date:

    Floating Rate Notes: October 27, 2028

    2028 Notes: October 27, 2028

    2030 Notes: October 29, 2030

    2032 Notes: October 29, 2032

    2035 Notes: October 29, 2035

     

    Coupon:

    Floating Rate Notes: Compounded SOFR (calculated as described in that certain preliminary prospectus supplement of the Issuer dated October 27, 2025), plus 0.660% per annum

    2028 Notes: 3.875%

    2030 Notes: 4.000%

    2032 Notes: 4.250%

    2035 Notes: 4.625%

     

     

    2

     

    Interest Payment Dates:

    Floating Rate Notes: Quarterly on each January 27, April 27, July 27 and October 27, commencing January 27, 2026

    2028 Notes: Semi-annually on each April 27 and October 27, commencing April 27, 2026

    2030 Notes: Semi-annually on each April 29 and October 29, commencing April 29, 2026

    2032 Notes: Semi-annually on each April 29 and October 29, commencing April 29, 2026

    2035 Notes: Semi-annually on each April 29 and October 29, commencing April 29, 2026

     

    Record Dates:

    Floating Rate Notes: January 12, April 12, July 12 and October 12

    2028 Notes: April 12 and October 12

    2030 Notes: April 14 and October 14

    2032 Notes: April 14 and October 14

    2035 Notes: April 14 and October 14

     

    Price to Public:

    Floating Rate Notes: 100.000% of principal amount

    2028 Notes: 99.855% of principal amount

    2030 Notes: 99.155% of principal amount

    2032 Notes: 98.743% of principal amount

    2035 Notes: 98.850% of principal amount

     

    Underwriting Discount:

    Floating Rate Notes: 0.200% of principal amount

    2028 Notes: 0.200% of principal amount

    2030 Notes: 0.300% of principal amount

    2032 Notes: 0.350% of principal amount

    2035 Notes: 0.450% of principal amount

     

    Net Proceeds:

    Floating Rate Notes: $299,400,000 (before expenses)

    2028 Notes: $747,412,500 (before expenses)

    2030 Notes: $741,412,500 (before expenses)

    2032 Notes: $836,340,500 (before expenses)

    2035 Notes: $836,400,000 (before expenses)

     

     

    3

     

    Benchmark Treasury:

    Floating Rate Notes: N/A

    2028 Notes: 3.500% due October 15, 2028

    2030 Notes: 3.625% due September 30, 2030

    2032 Notes: 3.875% due September 30, 2032

    2035 Notes: 4.250% due August 15, 2035

     

    Benchmark Treasury Price/Yield:

    Floating Rate Notes: N/A

    2028 Notes: 100-00 ¼ / 3.497%

    2030 Notes: 100-02 ¼ / 3.609%

    2032 Notes: 100-18 / 3.781%

    2035 Notes: 102-02+ / 3.991%

     

    Spread to Benchmark Treasury:

    Floating Rate Notes: N/A

    2028 Notes: +43 basis points

    2030 Notes: +58 basis points

    2032 Notes: +68 basis points

    2035 Notes: +78 basis points

     

    Yield to Maturity:

    Floating Rate Notes: N/A

    2028 Notes: 3.927%

    2030 Notes: 4.189%

    2032 Notes: 4.461%

    2035 Notes: 4.771%

     

    Optional Redemption:

    Floating Rate Notes:

    Except as noted under the caption “Description of Notes – Redemption for Tax Reasons” in the prospectus supplement, the Floating Rate Notes are not redeemable prior to maturity.

     

    2028 Notes:

    Prior to September 27, 2028: Make-whole redemption at Treasury plus 10 bps

    On or after September 27, 2028: Redemption at par

     

    2030 Notes:

    Prior to September 29, 2030: Make-whole redemption at Treasury plus 10 bps

    On or after September 29, 2030: Redemption at par

     

    2032 Notes:

    Prior to August 29, 2032: Make-whole redemption at Treasury plus 15 bps

    On or after August 29, 2032: Redemption at par

     

    2035 Notes:

    Prior to July 29, 2035: Make-whole redemption at Treasury plus 15 bps

    On or after July 29, 2035: Redemption at par

     

     

     

    4

     

    Settlement Date (T+2):

    October 29, 2025*

     

    CUSIP/ISIN: Floating Rate Notes: CUSIP Number: 718172 EB1
    ISIN Number: US718172EB10
         
      2028 Notes: CUSIP Number: 718172 DX4
    ISIN Number: US718172DX49
         
      2030 Notes: CUSIP Number: 718172 DY2
    ISIN Number: US718172DY22
         
      2032 Notes: CUSIP Number: 718172 DZ9
    ISIN Number: US718172DZ96
         
      2035 Notes: CUSIP Number: 718172 EA3
    ISIN Number: US718172EA37
         
    Listing:

    None

     

    Joint Book-Running Managers:

    BBVA Securities Inc.

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    Deutsche Bank Securities Inc.

    Wells Fargo Securities, LLC

    Goldman Sachs & Co. LLC

    HSBC Securities (USA) Inc.

    UBS Securities LLC

     

    Co-Managers:

    Bank of China (Europe) S.A.

    DBS Bank Ltd.

    Morgan Stanley & Co. LLC

     

     

    5

     

    Allocations:  Floating Rate Notes   2028 Notes   2030 Notes   2032 Notes   2035 Notes 
    BBVA Securities Inc.  $37,320,000   $93,300,000   $93,300,000   $105,740,000   $105,740,000 
    BofA Securities, Inc.   37,320,000    93,300,000    93,300,000    105,740,000    105,740,000 
    Citigroup Global Markets Inc.   37,320,000    93,300,000    93,300,000    105,740,000    105,740,000 
    Deutsche Bank Securities Inc.   37,320,000    93,300,000    93,300,000    105,740,000    105,740,000 
    Wells Fargo Securities, LLC   37,320,000    93,300,000    93,300,000    105,740,000    105,740,000 
    Goldman Sachs & Co. LLC   27,000,000    67,500,000    67,500,000    76,500,000    76,500,000 
    HSBC Securities (USA) Inc.   27,000,000    67,500,000    67,500,000    76,500,000    76,500,000 
    UBS Securities LLC   27,000,000    67,500,000    67,500,000    76,500,000    76,500,000 
    Bank of China (Europe) S.A.   10,800,000    27,000,000    27,000,000    30,600,000    30,600,000 
    DBS Bank Ltd.   10,800,000    27,000,000    27,000,000    30,600,000    30,600,000 
    Morgan Stanley & Co. LLC   10,800,000    27,000,000    27,000,000    30,600,000    30,600,000 
    Total  $300,000,000   $750,000,000   $750,000,000   $850,000,000   $850,000,000 

     

    * Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the delivery date will be required, by virtue of the fact that the Notes initially settle in T+2, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement.

     

    No EEA or UK PRIIPs KID – No EEA or UK PRIIPs key information document (KID) has been prepared as the notes are not available to retail investors in the EEA or the UK.

     

    The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling BBVA Securities Inc. toll free at 1-800-422-8692, BofA Securities, Inc. toll-free at 1-800-294-1322, Citigroup Global Markets Inc. toll free at 1-800-831-9146, Deutsche Bank Securities Inc. toll free at 1-800-503-4611 or Wells Fargo Securities, LLC toll free at 1-800-645-3751.

     

     

     

    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International upgraded by UBS with a new price target

    UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

    4/25/25 8:25:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Evolves Organizational Model to Advance Smoke-Free Future

    Effective January 1, 2026, Philip Morris International will introduce new U.S. and International Business Units to enable continued industry-leading smoke-free progress Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) is today further detailing a new corporate organizational model announced in conjunction with the company's 2025 third quarter results. The updated organizational structure, effective January 1, 2026, is designed to enhance PMI's agility and support its journey to becoming a smoke-free company under the leadership of Group CEO PMI Jacek Olczak. PMI's smoke-free business is currently operating at scale across its regions, including substantial growth from th

    11/4/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 2040

    The plan details actions, timelines, and targets for climate change mitigation and adaptation in the company's direct operations and the most vulnerable areas of its supply chain Philip Morris International Inc. (PMI) (NYSE:PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI's continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-rel

    11/3/25 5:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. Recognized for Workplace Excellence

    U.S. Businesses Honored as a Great Place to Work® and USA TODAY Top Workplace STAMFORD, Conn., Oct. 28, 2025 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) is proud to announce its recent certification as a Great Place to Work® and recognition as a USA TODAY Top Workplace, including honors as a Top Woman-Led Company and for excellence in professional development, employee appreciation, and well-being. "Being nationally recognized for our culture and people-first approach is a testament to the incredible teams at PMI U.S.," said Stacey Kennedy, PMI U.S

    10/28/25 1:06:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    11/4/25 7:06:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    10/29/25 4:05:56 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Philip Morris International Inc

    FWP - Philip Morris International Inc. (0001413329) (Subject)

    10/27/25 6:57:10 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

    Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth an

    10/21/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) has increased the company's regular quarterly dividend by 8.9% to an annualized rate of $5.88 per share. The new quarterly dividend of $1.47 per share, up from $1.35 per share, is payable on October 20, 2025, to shareholders of record as of October 3, 2025. The ex-dividend date is October 3, 2025. PMI has increased its annual dividend every year since becoming a public company in 2008, representing a total increase of 219.6%, or a compound annual growth rate of 7.1%. For additional dividend information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Ph

    9/19/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

    7/22/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

    3 - Philip Morris International Inc. (0001413329) (Issuer)

    6/9/25 3:34:30 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:43 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    3/4/24 6:48:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care